Clinical Trials Logo

Clinical Trial Summary

This is a multicenter, multiple expansion cohort, Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-0201 in adult patients with relapsed or refractory B-cell non-Hodgkin lymphoma.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06392477
Study type Interventional
Source Dren Bio
Contact Dren Central Contact
Phone 415-737-5277
Email clinops@drenbio.com
Status Recruiting
Phase Phase 1
Start date June 2024
Completion date December 2026

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03114865 - A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance Phase 1/Phase 2
Recruiting NCT04836195 - Phase I Trial of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma Phase 1
Active, not recruiting NCT04088890 - Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies Phase 1
Recruiting NCT05472558 - Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL Phase 1
Recruiting NCT04191941 - Treatment of Hematological Malignancy With Novel CAR-T Cells. Early Phase 1
Active, not recruiting NCT04148430 - A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy Phase 2
Recruiting NCT05702853 - Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL Phase 1/Phase 2
Not yet recruiting NCT05991388 - A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma Phase 2/Phase 3
Recruiting NCT04887012 - Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL Phase 1
Completed NCT04030195 - Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL Phase 1/Phase 2
Recruiting NCT04594642 - A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Phase 1
Recruiting NCT05338931 - Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma Phase 1/Phase 2
Recruiting NCT05164770 - Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma Phase 3
Completed NCT05260203 - MargheRITA (Remote Intelligence for Therapeutic Adherence) N/A
Active, not recruiting NCT05094206 - CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies Phase 1
Not yet recruiting NCT04412174 - A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL Early Phase 1
Completed NCT04748185 - Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies
Active, not recruiting NCT03283137 - Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL Phase 1
Completed NCT02910063 - Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL Phase 2/Phase 3
Recruiting NCT05744037 - Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells Phase 2